NFE2L2 and kidney disorder: Multiple studies have confirmed that genetic or pharmacological enhancement of Nrf2 activity in the renal tubules significantly ameliorated damage related to AKI and that targeting the Keap1-Nrf2 system could prevent kidney disease progression (Nezu et al., 2017).